null

TIMP2 Monoclonal Antibody (CAB20766)

SKU:
CAB20766
Product Type:
Antibody
Antibody Type:
Secondary Antibody
Host Species:
Goat
Isotype:
Fluorescein conjugated IgG
  • Western blot analysis of extracts of various cell lines, using TIMP2 antibody at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 60s.
  • Western blot analysis of extracts of various cell lines, using TIMP2 antibody at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Basic Kit. Exposure time: 20s.
€179 - €469
Frequently bought together:

Description

system_update_altDatasheetsystem_update_altMSDS

TIMP2 Monoclonal Antibody (CAB20766)

The Anti-TIMP2 Antibody (CAB20766) is a valuable tool for researchers studying tissue inhibitor of metalloproteinase 2 (TIMP2), a crucial regulator of extracellular matrix remodeling and tissue homeostasis. This polyclonal antibody, produced in rabbits, is highly specific and reactive with human samples, making it suitable for a variety of applications including Western blot and immunohistochemistry.TIMP2 is known for its role in inhibiting matrix metalloproteinases (MMPs), enzymes involved in tissue degradation and remodeling. Dysregulation of TIMP2 has been implicated in various pathological conditions such as cancer metastasis, fibrosis, and cardiovascular diseases.

The Anti-TIMP2 Antibody enables researchers to detect and analyze TIMP2 expression levels in different cell types and tissues, providing insights into its functions and potential therapeutic targets.With its high specificity and sensitivity, the Anti-TIMP2 Antibody is an essential tool for studies in the fields of cancer biology, tissue remodeling, and cardiovascular research. By understanding the role of TIMP2 in disease processes, researchers can potentially develop targeted therapies for conditions associated with dysregulated extracellular matrix dynamics.